Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Tammy Lee

Nurse Practitioner, Gerontology Belpre, OH Nurse Practitioner

NPI 1063168268 CMS profile 11359504

1818 Washington Blvd Ste F, Belpre, OH 45714

Open in the dashboard

General payments

$3,947

191 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tammy Lee of Belpre, OH is reported in the CMS Open Payments database as having received $3,947 across 191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,108 48
2024 General $1,400 70
2023 General $1,049 50
2022 General $391 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tammy Lee
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Tammy Lee were reported at $1,108. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Tammy Lee Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $391 $142 $48–$452 $149
2023 $1,049 $158 $53–$482 $160
2024 $1,400 $171 $55–$533 $164
2025 $1,108 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Lilly USA, LLC $760 40 payments
  2. Novo Nordisk Inc $501 31 payments
  3. Corcept Therapeutics $482 18 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $349 20 payments
  5. Sanofi-Aventis U.S. LLC $297 12 payments
  6. Averitas Pharma Inc. $182 9 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $162 5 payments
  8. AstraZeneca Pharmaceuticals LP $140 4 payments
  9. Insulet Corporation $139 7 payments
  10. Beta Bionics, Inc. $126 3 payments
  11. Other $810 42 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,857 186 payments
  2. Education $90 5 payments
Products named General payments · program years 2022–2025
  1. Korlym $482 18 payments
  2. MOUNJARO $358 22 payments
  3. Ozempic $298 19 payments
  4. RYBELSUS $298 19 payments
  5. ZEPBOUND $276 10 payments
  6. TZIELD $273 10 payments
  7. JARDIANCE Diabetes $245 15 payments
  8. JARDIANCE Diabetes $229 14 payments
  9. Qutenza $182 9 payments
  10. Kerendia $162 5 payments
  11. Other $2,039 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,937

Median for Nurse Practitioner: 389

Drug cost

$1,201,741

Median for Nurse Practitioner: $21,885

Branded share of claims

59.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 229 $284,564
Ozempic Semaglutide Brand 169 $231,534
Jardiance Empagliflozin Brand 191 $199,969
Trulicity Dulaglutide Brand 86 $135,807
Tresiba Flextouch U-100 Insulin Degludec Brand 74 $47,259
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 43 $42,894
Tresiba Flextouch U-200 Insulin Degludec Brand 43 $34,565
Farxiga Dapagliflozin Propanediol Brand 26 $33,947
Januvia Sitagliptin Phosphate Brand 30 $26,542
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 215 $25,372

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$30,641

Medicare's payments for the services billed

Medicare patients

254

Average age 71

Services billed

681

166 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 59%
Depression 32%
Chronic kidney disease 31%
Ischemic heart disease 28%
Osteoporosis 27%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $147
  • Lilly USA, LLC $83
$229 191 —
ZEPBOUND
  • Lilly USA, LLC $181
$181 — —
MOUNJARO
  • Lilly USA, LLC $134
$134 229 —
Qutenza
  • Averitas Pharma Inc. $104
$104 — —
Korlym
  • Corcept Therapeutics $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record